Related Experiment Video
Updated: Jun 26, 2026

Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
Persistent interferon signaling and clonal expansion mark early events in DNA methylation damage-induced liver cancer
Lee J Pribyl1, Jennifer E Kay1,2, Joshua J Corrigan1
1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139, United States.
Abstract:
N-Nitrosodimethylamine (NDMA), a probable human carcinogen, induces toxic and mutagenic DNA O 6-methylguanine (O 6MeG) adducts that are repaired by O 6-methylguanine-DNA methyltransferase (MGMT). To elucidate how early-life environmental mutagenic exposures promote latent liver tumorigenesis, we performed longitudinal studies in wild-type and MGMT-deficient (Mgmt -/-) mice. Neonatal mice received NDMA intraperitoneally on postnatal days 8 and 15 and were followed for up to 10 months post-exposure. Phenomics, transcriptomics, phosphoproteomics, spatial transcriptomics, and histopathology revealed that NDMA exposure in Mgmt -/- mice produced a nine-fold increase in liver tumors, including hepatocellular carcinomas and adenomas. Early molecular profiling revealed elevated O 6MeG adducts, sustained γH2AX activation, and increased micronucleus formation in Mgmt -/- livers. Transcriptomics showed persistent interferon response and immune cell infiltration, particularly in Mgmt -/- mice, up to 10 months post-exposure. Clonal expansion, quantified by RaDR-GFP expression, was significantly higher in NDMA-exposed Mgmt -/- mice. Spatial transcriptomics of clonally expanded cells demonstrated activation of oncogenic and inflammatory pathways. These findings demonstrate that acute early-life NDMA exposure drives persistent DNA damage signaling, chronic interferon activation, and clonal expansion that together promote MGMT-dependent hepatocarcinogenesis. Collectively, these processes link early environmental mutagen exposure to long-term premalignant evolution and tumor emergence, and define mechanistic biomarkers and potential interception targets for NDMA-induced liver cancer.
Insights
Early exposure to the carcinogen NDMA significantly increases liver tumors in mice lacking DNA repair. This damage triggers inflammation and cell growth, promoting cancer development.
Area of Science:
- Hepatocarcinogenesis research
- Environmental toxicology
- DNA repair mechanisms
Background:
- N-Nitrosodimethylamine (NDMA) is a probable human carcinogen.
- NDMA induces DNA adducts repaired by O6-methylguanine-DNA methyltransferase (MGMT).
- Early-life mutagen exposure can promote latent liver tumorigenesis.
Purpose of the Study:
- To investigate how early-life NDMA exposure promotes liver tumorigenesis.
- To elucidate the role of MGMT in mediating NDMA-induced hepatocarcinogenesis.
- To identify molecular mechanisms linking mutagen exposure to liver cancer.
Main Methods:
- Longitudinal studies in wild-type and MGMT-deficient (Mgmt-/-) mice.
- NDMA administration on postnatal days 8 and 15.
- Multi-omics profiling (phenomics, transcriptomics, phosphoproteomics, spatial transcriptomics) and histopathology.
Main Results:
- NDMA exposure caused a nine-fold increase in liver tumors in Mgmt-/- mice.
- Elevated O6MeG adducts, sustained γH2AX activation, and micronucleus formation were observed.
- Persistent interferon response, immune cell infiltration, and clonal expansion were prominent in Mgmt-/- mice.
- Spatial transcriptomics revealed activation of oncogenic and inflammatory pathways in clonally expanded cells.
Conclusions:
- Acute early-life NDMA exposure drives persistent DNA damage signaling, chronic interferon activation, and clonal expansion.
- These processes promote MGMT-dependent hepatocarcinogenesis.
- Early mutagen exposure links to long-term premalignant evolution and tumor emergence, identifying biomarkers and interception targets for NDMA-induced liver cancer.
Related Concept Videos
Epigenetic Regulation
X-chromosome...
Epigenetic Regulation
Mutagenicity and Carcinogenicity
Inhibitors of Viral Protein Synthesis
Non-LTR Retrotransposons
Mechanisms of Retrovirus-induced Cancers

